Cure8 research brief
Findings could affect how microbiota-based therapies for chronic pouchitis are developed, and they highlight antibiotic resistance in E. coli from inflamed pouches that may influence antibiotic selection or resistance surveillance.
Researchers studying the microbiome, clinicians treating pouchitis and IBD, and patients interested in microbiome-based therapies or antibiotic resistance in pouchitis.
Researchers sequenced fecal samples from 190 participants using short- and long-read metagenomics and reconstructed over 12,000 metagenome-assembled genomes (MAGs). The analysis highlighted differences between pouch and colon microbiomes and identified antibiotic-resistance features linked to E. coli and plasmids in chronically inflamed pouches.
The authors suggest that using HealthyPouch-derived microbiota might be a better source than NormalGut donors if fecal microbiota transplantation (FMT) is considered for chronic pouchitis, and they emphasize including plasmid analysis when assessing resistance for personalized antibiotic strategies.
The report describes genomic associations and does not provide clinical treatment recommendations or trial results for FMT or specific antibiotics.
This entry is based on the journal abstract and metagenomic analysis described there (structured content depth: abstract). The study reports genomic associations and sequencing results; it does not present clinical trial outcomes or direct evidence that HealthyPouch-based FMT is effective.
Plasmid and resistance findings are genomic and suggest areas for further clinical research and surveillance.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Intestinal barrier dysfunction is a likely driver of inflammation and flares in ulcerative colitis, so therapies that restore barrier integrity could help reduce disease activity and recurrence. This review highlights...
Antibiotics can substantially change gut microbes; for people with IBD those changes may affect inflammation and gut barrier function. The review summarizes microbiome-targeted strategies that patients and clinicians may...
People with ulcerative colitis may be interested because the review explains how the gut microbiome and its metabolites could influence disease and evaluates whether traditional Chinese medicines might modify those...
